Novartis is looking to use more mobile technology in its clinical trials and to provide connectivity for future Novartis products. Novartis will use Qualcomm Life’s 2net platform and various connected devices to collect medical data directly from trial participants in their homes.
The first trial in the new partnership has already begun, evaluating the use of mobile devices for patients with chronic lung conditions. The trial is observational and doesn’t involve any Novartis products or other pharmaceuticals. According to Qualcomm, the study “leverages 2net mobile-enabled smartphones and 2net Hubs to seamlessly collect and aggregate biometric data from medical devices and transmits this data to the cloud-based 2net Platform, which securely sends the data to the study coordinator.”